Normalizing hematocrit in dialysis patients improves brain function.
about
Erythropoietin enhances hippocampal long-term potentiation and memoryErythropoietin Pathway: A Potential Target for the Treatment of DepressionIron deficiency anemia in inflammatory bowel diseaseCognitive changes associated with switching to frequent nocturnal hemodialysis or renal transplantation.Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapyHemodilutional anemia is associated with increased cerebral neuronal nitric oxide synthase gene expression.A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia.The pathological consequences of anaemia.Brain and cancer: the protective role of erythropoietin.Anemia is associated with depression in older adults: results from the InCHIANTI study.Darbepoetin alfa: a novel erythropoiesis-stimulating protein.Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies.Nephrology: 4. Strategies for the care of adults with chronic kidney disease.Determinants of academic performance in children with sickle cell anaemia.The pleiotropic effects of erythropoietin in the central nervous system.Cerebral microbleeds and cognitive decline in a hemodialysis patient: Case report and review of literatureIron, anaemia, and inflammatory bowel diseases.Anemia, cancer, and aging.Predictors of anemia in a multi-ethnic chronic kidney disease population: a case-control study.The nervous system and chronic kidney disease in childrenActivating mitochondrial function and haemoglobin expression with EH-201, an inducer of erythropoietin in neuronal cells, reverses memory impairmentReport of an NIH task force on research priorities in chronic kidney disease in children.Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptideSenior adult oncology.Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysisErythropoietin crosses the blood-brain barrier to protect against experimental brain injury.Use of agents stimulating erythropoiesis in digestive diseasesA randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.Nervous system autoantibodies and vitamin D receptor gene polymorphisms in hemodialysis patients.Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease.Cerebral blood flow velocity and language functioning in pediatric sickle cell disease.Neuropsychiatric complications of chronic kidney disease.Seeing old friends from a different angle: novel properties of hematopoietic growth factors in the healthy and diseased brain.Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.Neurocognitive profile of an adult sample with chronic kidney disease.Prostaglandin D2 synthase: Apoptotic factor in alzheimer plasma, inducer of reactive oxygen species, inflammatory cytokines and dialysis dementia.Functional and anatomical evidence of cerebral tissue hypoxia in young sickle cell anemia mice.Anaemia in the elderly.
P2860
Q21245342-D26C7B51-B49F-463A-B5EF-22CA00642CD1Q26750850-2D1D6C20-3114-42D6-AFD2-1FC73516158AQ26795390-4108F11B-D4D2-46F1-B10B-E4076CC01623Q30277689-3A3AB7F2-4673-4165-81F6-0346F717B94DQ30749943-DAEBA58E-2D87-4A77-B70A-1B16A91EB9F3Q30762229-3D9F1B4B-9C66-4715-9213-B08AC563BF8EQ33770093-41BE6C7A-74CE-4D1D-8E10-AF574D53CB05Q33941377-4ACBDA3C-7C46-497E-90F5-0D84470B1258Q34291421-E4FEBD31-878A-4309-BD7F-A484664FF248Q34351447-8C378B37-4236-4C9F-B67F-D7C906FFA3C9Q34453821-BB4651C7-5C3B-4606-82E3-A21B08101557Q34709820-B49540FE-3760-4C64-8987-16C5EA686C93Q35021612-2D8AACE6-AA61-43BA-A665-AB0906235A13Q35031111-891BDC9F-4A92-4E4E-87FF-5C532317C3F9Q35045846-FB4B7076-AC0C-4065-BE4B-19BCFB3A36EFQ35085836-FABDDD33-9EA5-44C1-864D-B0662B54BC63Q35133379-5F63B65C-27FC-41CB-A6C7-814632A07879Q35596692-F81A4DC6-B9F6-4CA4-8F66-8638D9DDF6B1Q35599070-1A895479-A91D-46F8-8A97-09286447ACBDQ35811858-8D25A36E-E852-4A48-A2B8-03D9CE5E23B9Q35819555-C7D4380D-0B4C-4A2E-AA37-D447783F910BQ36124238-2B69842B-2BEF-4DE8-A84D-6CD46AF3D97EQ36298407-5366CC6B-1062-4535-8F90-E7ACCB74004BQ36736105-BA75179B-FC2F-4B86-B776-BF78950C0DC4Q36842139-8DF1FC90-901C-424B-825A-B4A2180185ADQ36851424-EBF7E7BB-D3DB-4482-A0BC-74AFA226FF7DQ37213727-AB50FB97-1E25-466E-B208-D4277976D646Q37250532-B27304AD-EF0E-4CBE-8A58-400B11ADA5FDQ37368733-3DF7F589-5635-4F98-89CD-0439BD7BC993Q37415720-D1E6D9D1-BBD1-48AA-A90D-59415FAA4710Q37572239-BAE86B9D-5FB0-46C3-A38C-65D88254AB6CQ37658582-9820AD84-AC17-461F-A65F-97FC0E4D445DQ37686573-5D19BFED-38AB-4EE8-80AC-A59425424FA7Q37766749-454FFD17-BABC-47FA-AC70-C602818BB49FQ37817069-0B6AF0AB-3DD0-4740-B5E2-BCA8EE6721CDQ37938732-A39BD7D0-C741-47FA-8543-93B1191858FBQ39818931-7580E169-7CBC-40A7-AF5F-0E964A7ACD32Q41870466-57558676-2631-40D2-9365-BED5B147B236Q42493001-B766F726-FDB7-4244-9A32-946EBA33C5F0Q43265727-6F8555A0-F646-4EBD-A1D4-FAEEC951BE75
P2860
Normalizing hematocrit in dialysis patients improves brain function.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Normalizing hematocrit in dialysis patients improves brain function.
@en
type
label
Normalizing hematocrit in dialysis patients improves brain function.
@en
prefLabel
Normalizing hematocrit in dialysis patients improves brain function.
@en
P2093
P1476
Normalizing hematocrit in dialysis patients improves brain function.
@en
P2093
Nissenson AR
Pickett JL
Schweitzer SU
Theberge DC
P304
P356
10.1016/S0272-6386(99)70150-2
P577
1999-06-01T00:00:00Z